Author:
Mara Rambo Martini Angela,Neris Cazella Luciane,Martini Yuri,Viapiana Bossa Adriane,Souza Santos Jefferson
Abstract
Prostate cancer (PC) is reported as an important neoplasm worldwide, caused by the uncontrolled multiplication of cells in the prostate. The main risk factors are age over 50 years, family history, genetic susceptibility, hormonal disorders, obesity and environmental factors. Active surveillance of low-risk PC defers aggressive treatment until disease progression and is an increasingly recommended treatment strategy. This strategy aims to reduce costs and decrease treatment-related morbidity without affecting survival. Medicinal Biomagnetism (BM) is based on the distortion of the limit of homeostasis towards hyperacidity and hyperalkalinity of two specific points for each pathogenic microorganism or glandular dysfunction. The induction of loads that are in a vibrational and energetic relationship, by means of medium intensity magnets, greater than 1000 Gauss, corrects or prevents the distortion of the pH of the organs or tissues of the human body. In this way, the neutralization of pathogenic bioenergetic distortions promotes health. The aim of this study was to evaluate the effect of BM in the treatment of prostatic adenocarcinoma, prognostic group 1. After three sessions of BM, the levels of prostate-specific antigen (PSA) decreased and the prostate adenocarcinoma regressed to discrete chronic inflammation. This study represents the first in the evaluation of BM for the treatment of CP and may stimulate further studies in this field that are likely to yield important discoveries.
Reference42 articles.
1. AMERICAN CANCER SOCIETY. Cancer Statistics Center, 2021. Disponível em: . Acesso em: 5 out. 2021a.
2. AMERICAN CANCER SOCIETY. Key Statistics for Prostate Cancer. Disponível em: . Acesso em: 5 out. 2021b.
3. BERRO, Tala; BARRETT, Elizabeth; ALDUBAYAN, Saud H. Clinical multigene testing for prostate cancer. The Urologic Clinics of North America, v. 48, n. 3, p. 297-309, 2021.
4. BHANJI, Yasin; ISAACS, William B.; XU, Jianfeng; COONEY, Kathleen A. Prostate Cancer Predisposition. Urologic Clinics of North America, v. 48, n. 3, 283-296, 2021.
5. BRASIL. Ministério da Saúde. Secretaria de Assistência à Saúde. Instituto Nacional de Câncer José Alencar Gomes da Silva. Estimativa 2020: Câncer de Próstata. Rio de Janeiro: INCA, 12 mai. 2020. Disponível em: . Acesso em 06 out. 2021.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献